TCH regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:Docetaxel-Carboplatin-Trastuzumab Regimen; Taxotere-Carboplatin-Herceptin Regimen; TCH Regimen
Overview
TCH regimen refers to a sequential regimen consisting of multiple cycles of docetaxel (taxotere), carboplatin and trastuzumab (herceptin), followed by multiple cycles of trastuzumab alone, administered as a dose-dense regimen, and used in the adjuvant setting for the treatment of HER-2/neu-positive breast cancer.[1][2]
Regimen
TDocetaxel (Taxotere)
CCarboplatin
HTrastuzumab (Herceptin)
Indications
- HER-2/neu-positive breast cancer.[1]
References
- ↑ 1.0 1.1 Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M; et al. (2011). “Adjuvant trastuzumab in HER2-positive breast cancer”. N Engl J Med. 365 (14): 1273–83. doi:10.1056/NEJMoa0910383. PMC 3268553. PMID 21991949.
- ↑ “NCI Thesaurus”.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH